Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79924.180.1047%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Nuvation Bio Inc

NUVBNYSE
Trade with Public
Trade with Public
$6.81
0.040.59%
At close: Sep 4, 5:00 PM EST
$6.82
0.010.15%
After Hours: Sep 4, 4:02 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Nuvation Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nuvation Bio (NUVB).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy
10Buy
1Hold
Consensus RatingBuy# Analysts13Avg. Consensus PT$11Upside to Avg. PT+59.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026Cantor FitzgeraldLi WatsekInitiateOverweight—
Aug 18, 2026JP MorganPriyanka GroverInitiateOverweight$13
More with Benzinga EdgeGet Access

Analyst Ratings News

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
Avi Kapoor

This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.
Avi Kapoor

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Nuvation Bio with Overweight Rating

Cantor Fitzgerald analyst Li Watsek initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating.
Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13

JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $19 to $20.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved